JP6696899B2 - プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用 - Google Patents

プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用 Download PDF

Info

Publication number
JP6696899B2
JP6696899B2 JP2016534815A JP2016534815A JP6696899B2 JP 6696899 B2 JP6696899 B2 JP 6696899B2 JP 2016534815 A JP2016534815 A JP 2016534815A JP 2016534815 A JP2016534815 A JP 2016534815A JP 6696899 B2 JP6696899 B2 JP 6696899B2
Authority
JP
Japan
Prior art keywords
seq
pai
heavy chain
light chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016534815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529255A (ja
JP2016529255A5 (enExample
Inventor
アラ・プリッツカー
パトリック・グライエ
アレクセイ・ラク
マガリ・マチュー
クリストファー・ライアン・モーガン
ニコラ・ボラン
ブリュノ・ポワリ
シリル・デイブ
フランシス・ドゥフィユー
ハン・リー
ドロシア・コミノス
フィリップ・ジャニャク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority claimed from PCT/US2014/050896 external-priority patent/WO2015023752A1/en
Publication of JP2016529255A publication Critical patent/JP2016529255A/ja
Publication of JP2016529255A5 publication Critical patent/JP2016529255A5/ja
Priority to JP2020076578A priority Critical patent/JP6907380B2/ja
Application granted granted Critical
Publication of JP6696899B2 publication Critical patent/JP6696899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2016534815A 2013-08-13 2014-08-13 プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用 Active JP6696899B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020076578A JP6907380B2 (ja) 2013-08-13 2020-04-23 プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361865451P 2013-08-13 2013-08-13
US61/865,451 2013-08-13
EP14305757.8 2014-05-22
EP14305757 2014-05-22
PCT/US2014/050896 WO2015023752A1 (en) 2013-08-13 2014-08-13 Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020076578A Division JP6907380B2 (ja) 2013-08-13 2020-04-23 プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2016529255A JP2016529255A (ja) 2016-09-23
JP2016529255A5 JP2016529255A5 (enExample) 2018-06-28
JP6696899B2 true JP6696899B2 (ja) 2020-05-20

Family

ID=56194112

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016534815A Active JP6696899B2 (ja) 2013-08-13 2014-08-13 プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用
JP2020076578A Active JP6907380B2 (ja) 2013-08-13 2020-04-23 プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用
JP2021107196A Active JP7223069B2 (ja) 2013-08-13 2021-06-29 プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
JP2023014335A Active JP7568756B2 (ja) 2013-08-13 2023-02-02 プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
JP2024172861A Active JP7764565B2 (ja) 2013-08-13 2024-10-02 プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
JP2025177454A Pending JP2026031550A (ja) 2013-08-13 2025-10-22 プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2020076578A Active JP6907380B2 (ja) 2013-08-13 2020-04-23 プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用
JP2021107196A Active JP7223069B2 (ja) 2013-08-13 2021-06-29 プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
JP2023014335A Active JP7568756B2 (ja) 2013-08-13 2023-02-02 プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
JP2024172861A Active JP7764565B2 (ja) 2013-08-13 2024-10-02 プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
JP2025177454A Pending JP2026031550A (ja) 2013-08-13 2025-10-22 プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用

Country Status (19)

Country Link
US (4) US9845363B2 (enExample)
EP (1) EP4707306A2 (enExample)
JP (6) JP6696899B2 (enExample)
KR (1) KR20160035077A (enExample)
CN (2) CN112142845A (enExample)
BR (1) BR112016002753A2 (enExample)
CL (1) CL2016000324A1 (enExample)
CR (2) CR20190319A (enExample)
DK (1) DK3620472T3 (enExample)
DO (1) DOP2016000042A (enExample)
EA (1) EA033403B1 (enExample)
ES (1) ES2770507T3 (enExample)
HK (1) HK1221725A1 (enExample)
MX (2) MX2016001851A (enExample)
PE (1) PE20160244A1 (enExample)
PH (1) PH12016500239A1 (enExample)
SG (1) SG10201710013RA (enExample)
TN (1) TN2016000048A1 (enExample)
UA (1) UA118267C2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033403B1 (ru) * 2013-08-13 2019-10-31 Sanofi Sa Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
TWI624267B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
CN108210899A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗组织器官纤维化的药物及其用途
US11129880B2 (en) * 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
TW201822805A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
WO2018107699A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗药物性肾损伤的方法
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
MA47691A (fr) * 2017-08-03 2020-01-08 Alector Llc Anticorps anti-cd33 et leurs procédés d'utilisation
WO2020140101A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
US20220340665A1 (en) 2019-09-30 2022-10-27 Renascience Inc. Inhibitor against expression of immune checkpoint molecule
AU2020373161A1 (en) * 2019-10-28 2022-05-26 Monash University Antibodies for binding plasminogen
IL293195A (en) * 2019-12-05 2022-07-01 Seagen Inc Anti-avb6 antibodies and antibody-drug conjugates
JP7616697B2 (ja) * 2020-02-11 2025-01-17 タレンゲン インターナショナル リミテッド ウイルス性肺炎を治療する方法及び薬剤
CN111072780B (zh) * 2020-03-24 2020-06-23 深圳汉盛汇融再生医学科技有限公司 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用
EP4225787A4 (en) * 2020-05-21 2024-10-23 Zydus Lifesciences Limited FC VARIANT AND PRODUCTION THEREOF
CN114605550B (zh) * 2020-12-08 2023-09-22 东莞市朋志生物科技有限公司 抗ca19-9的抗体、其应用和检测ca19-9的试剂盒
CN114686442B (zh) * 2020-12-31 2023-11-07 广州万孚生物技术股份有限公司 一种杂交瘤细胞株及其应用
CN114686441B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 一种能分泌tPAI-C单克隆抗体的杂交瘤细胞株及其应用
CN115873120B (zh) * 2022-09-08 2025-10-21 厦门英博迈生物科技有限公司 一种纤溶酶α2纤溶酶抑制物复合物抗体及应用
CN116355091A (zh) * 2023-03-27 2023-06-30 陕西师范大学 一种抗人神经丝轻链的单克隆抗体21d2-30d3及其产品和应用
WO2025032553A1 (en) * 2023-08-10 2025-02-13 Cochlear Limited Methods of treating inner ear fibrosis
CN121554575B (zh) * 2026-01-22 2026-04-07 华中农业大学 猪δ冠状病毒N蛋白单克隆抗体及含有该抗体的乳胶免疫层析试纸条

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5422245A (en) * 1985-07-12 1995-06-06 Fonden Til Fremme Af Eksperimental Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
US6271352B1 (en) * 1985-07-12 2001-08-07 Fonden Til Fremme Af Eksperimentel Cancerforskning PAI-1 determination and use thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
JP2750732B2 (ja) * 1988-04-04 1998-05-13 帝人株式会社 ヒトプラスミノーゲンアクティベーターインヒビター・１−ヒト組織プラスミノーゲンアクティベーター複合体の免疫学的測定方法
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JPH1014592A (ja) * 1996-07-04 1998-01-20 Tanabe Seiyaku Co Ltd ラットｐａｉ−１に対するモノクローナル抗体
WO1998005787A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2001229441A1 (en) * 2000-01-14 2001-07-24 Tanox, Inc. Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
AU2002216847A1 (en) 2000-10-26 2002-05-06 K.U. Leuven Research And Development Epitopes of pai-1
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
WO2004041155A2 (en) * 2002-05-13 2004-05-21 Children's Hospital Los Angeles Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2004035752A2 (en) 2002-10-15 2004-04-29 Protein Design Labs, Inc. ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US7833260B2 (en) 2006-07-20 2010-11-16 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
US20090202524A1 (en) 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
US7771720B2 (en) 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
US20100254979A1 (en) * 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
US20120114652A1 (en) * 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
EA033403B1 (ru) * 2013-08-13 2019-10-31 Sanofi Sa Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения

Also Published As

Publication number Publication date
US20180155444A1 (en) 2018-06-07
KR20160035077A (ko) 2016-03-30
TN2016000048A1 (en) 2017-07-05
EA033403B1 (ru) 2019-10-31
JP7568756B2 (ja) 2024-10-16
MX2016001851A (es) 2016-05-16
CN105705520B (zh) 2020-09-25
JP7223069B2 (ja) 2023-02-15
UA118267C2 (uk) 2018-12-26
US9845363B2 (en) 2017-12-19
JP2021155440A (ja) 2021-10-07
CR20190319A (es) 2019-08-29
HK1221725A1 (zh) 2017-06-09
JP2023055852A (ja) 2023-04-18
US20190359729A1 (en) 2019-11-28
JP2026031550A (ja) 2026-02-24
MX2019008803A (es) 2019-09-16
US20160200831A1 (en) 2016-07-14
SG10201710013RA (en) 2018-01-30
PE20160244A1 (es) 2016-05-10
JP2020125333A (ja) 2020-08-20
CN112142845A (zh) 2020-12-29
ES2770507T3 (es) 2020-07-01
BR112016002753A2 (pt) 2017-11-21
DK3620472T3 (da) 2026-04-07
JP6907380B2 (ja) 2021-07-21
EP4707306A2 (en) 2026-03-11
JP2016529255A (ja) 2016-09-23
CN105705520A (zh) 2016-06-22
JP2025011161A (ja) 2025-01-23
DOP2016000042A (es) 2016-04-04
US20230015181A1 (en) 2023-01-19
EA201690377A1 (ru) 2016-06-30
CR20160117A (es) 2016-05-20
CL2016000324A1 (es) 2016-10-21
PH12016500239A1 (en) 2016-05-16
JP7764565B2 (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
JP7764565B2 (ja) プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
TWI592426B (zh) 胞漿素原活化素抑制劑－１（ｐａｉ－１）之抗體及其用途
CN110248964B (zh) 促凝血抗体
KR102035882B1 (ko) 브라디키닌 b1 수용체 리간드에 대한 항체
PT2542257T (pt) Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
HK40044528A (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
HK40023283A (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
HK40023283B (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
HK1206754B (en) Antibodies to bradykinin b1 receptor ligands

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200423

R150 Certificate of patent or registration of utility model

Ref document number: 6696899

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250